Valuation: ImmuCell Corporation

Market Cap 93.09M 81.38M 74.79M 69.71M 132M 8.86B 134M 898M 349M 4.36B 349M 342M 15.01B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 102M 89.59M 82.33M 76.74M 146M 9.76B 148M 988M 384M 4.8B 385M 376M 16.53B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.43%
Yield 2024 *
-
Yield 2025 -
1 day-6.45%
1 week+5.11%
Current month+2.39%
1 month+2.39%
3 months+59.78%
6 months+73.82%
Current year+67.32%
1 week 9.68
Extreme 9.68
11.16
1 month 9.25
Extreme 9.25
11.16
Current year 5.75
Extreme 5.75
11.16
1 year 4.52
Extreme 4.52
11.16
3 years 3.34
Extreme 3.34
11.16
5 years 3.34
Extreme 3.34
11.16
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-10-31
Director of Finance/CFO 47 2025-04-06
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 2013-11-30
Director/Board Member 61 2014-03-30
Director/Board Member 66 2020-06-09
Date Insider Type Main position Quantity % Market Cap.
06-17Buy

Chief Executive Officer

8,000 0.0884%
04-14Free

Director

11,933 0.1319%
04-14Free

Director

17,899 0.1979%
Change 5-day change 1-year change 3-year change Capi.($)
-6.45%+5.11%+60.91%+99.42% 93.09M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.24%+4.79%+34.69%+62.34% 369.98B
Weighted average by Cap. +2.24%+5.69%+42.24%+83.14%

Financials

2024 2025
Net sales 26.49M 23.16M 21.28M 19.84M 37.63M 2.52B 38.2M 256M 99.33M 1.24B 99.44M 97.31M 4.27B 27.64M 24.17M 22.21M 20.7M 39.26M 2.63B 39.86M 267M 104M 1.29B 104M 102M 4.46B
Net income -2.16M -1.89M -1.73M -1.61M -3.06M -205M -3.11M -20.8M -8.09M -101M -8.1M -7.92M -348M -1.04M -909K -836K -779K -1.48M -99.03M -1.5M -10.03M -3.9M -48.68M -3.9M -3.82M -168M
Net Debt 11.34M 9.91M 9.11M 8.49M 16.11M 1.08B 16.35M 109M 42.52M 531M 42.57M 41.66M 1.83B 9.39M 8.21M 7.54M 7.03M 13.33M 894M 13.54M 90.54M 35.2M 439M 35.24M 34.48M 1.51B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
26-07-02 US$10.29 -6.45% 41,066
26-07-01 US$11.00 +9.45% 56,155
26-06-30 US$10.05 +1.41% 69,176
26-06-29 US$9.910 +1.23% 21,710
26-06-26 US$9.790 -1.01% 26,894
  1. Stock Market
  2. Stocks
  3. ICCC Stock